Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
6 signals in the last 90 days.
The order this company entered each market — oldest to newest
Gan & Lee Partners with JW Pharmaceutical
Gan & Lee Partners with JW Pharmaceutical
Sign up to see the full signal feed
How Gan & Lee Pharmaceuticals's international expansion compares to its competitors
Gan & Lee PharmaceuticalsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Gan & Lee PharmaceuticalsYou | 2 | 1 | -100% | 6 | 49 |
Regulatory Affairs VP
View postingBandar Banang Jaya, Johore, Malaysia · 9mo ago
Senior Manager, Regulatory Affairs - EU
View postingGermany · 11mo ago
principal investigator of Biopharmaceuticals
View postingBeijing, China · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Gan & Lee Pharmaceuticals to present three abstracts on investigational diabetes products at ADA's 84th Scientific Sessions in Orlando, Florida.
FDA clears Gan & Lee's GZR18 for phase 2 trial, comparing it with Eli Lilly's Tirzepatide for obesity treatment.
Gan & Lee starts Phase 2 trial of bofanglutide for obesity, comparing it head-to-head with tirzepatide in the US.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Gan & Lee Pharmaceuticals's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
